Navigation Links
Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
Date:1/30/2013

LONDON, January 30, 2013 /PRNewswire/ --

EmergingGrowth.com, a leading digital financial media company, discusses Sunesis Pharmaceuticals, Amgen, Inc., Gilead Sciences and Biogen Idec, Inc.

The pharmaceutical sector is a very lucrative and competitive industry. And for emerging growth companies, it is difficult to make a meaningful impact in this cutthroat industry.

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, Vosaroxin, to improve the lives of people with cancer.

Sunesis Pharmaceuticals' work translates to a rosy top line as demonstrated by the $25 million it earned from a previously announced royalty purchase agreement with Royalty Pharma. It took possession of $15 million from the second tranche of a 2011 venture loan facility. It raised $17.3 million from the sale of 3.6 million shares of common stock and $1.4 million from the gross exercise of 0.6 million warrants to purchase common stock. This not only shows that Sunesis is able to raise capital for research purposes, but it also represents the company's keen interest in creating shareholder value.

The company is in the follow-up stage of trials of Vosaroxin, having completed a Phase 2 trial in ovarian cancer patients in 2010. However, broader market tailwinds will propel the company through the next decade. Vosaroxin is a first-in-class anticancer quinolone derivative, a class of compounds that has not been used previously for the treatment of cancer.  As of now, notable breakthroughs are being made with the drug, particularly as complete remissions have been observed in patients treated with Vosaroxin in combination with Cytarabine.

Just like its bigger competitors, Amgen Inc. (NASDAQ: AMGN) and Gilead Sciences Inc. (NASDAQ: GILD), Sunesis also wants to make a big impact. To ensure this, it has entered into a collaboration agreement with Millennium Pharmaceuticals for the development of Sunesis' inhibitor. It also announced the license of the company's LFA-1 inhibitor program to SARcode Corporation, a privately held bio-pharmaceutical company. In addition, it has announced a collaboration agreement with Biogen Idec Inc. (NASDAQ: BIIB) to discover, develop, and commercialize inhibitors of Raf kinase and up to five additional oncology kinase targets.

All these developments will signal the market's gravitation toward Sunesis products. Considering that ovarian cancer is the eighth most common cancer among women, it would be accurate to say that vosaroxin will be relevant in the market. In addition, the future promise of FDA approval brightens the long-term picture and promises longevity. With a market capitalization of $226 million and a 52-week range $1.29 - $6.85 (the stock is currently trading close to its high at around $4), it would be accurate to say that Sunesis Pharmaceuticals will gain tremendous value in the next few years.

NEW:  Feature your company on EmergingGrowth.com.  Find out how by filling out our referral form here: http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth

About EmergingGrowth.com

By offering 100% original and unmatched content by the best financial reporters, writers and bloggers in the business, EmergingGrowth.com is emerging as a leading digital financial media portal. Its services provide users, subscribers and advertisers with a variety of content and tools through a range of online, social media, mobile and other mobile outlets.

Since its inception, EmergingGrowth.com has distinguished itself from other financial media companies with its sly approach to reading between the lines in order to locate that needle in the haystack.  Sign up today to see what EmergingGrowth.com has to offer.

Join our LinkedIn Group…  http://www.linkedin.com/groups/?gid=4650356&trk=hb_side_g

Like us on Facebook... http://www.facebook.com/pages/EmergingGrowthcom/474647062557938

Disclosure

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. In addition, Please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website. Always remember that investing in securities such as the ones listed within are for high-risk tolerant individuals only and not the general public. Whether you are an experienced investor or not, you should always consult with a stockbroker, financial advisor, or similar before purchasing or selling any securities viewed on any emails sent from EmergingGrowth.com or its website.


'/>"/>
SOURCE EmergingGrowth.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Emerging Technologies Expands Life Sciences Center
2. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
3. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
4. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
5. Henry Schein Announces Featured Speakers For The "Recovery Empowerment Symposium: Emerging From The Storm"
6. Cepheid Announces Executive Vice President Emerging Markets
7. Emerging Pharma Catalysts: H2 2012
8. As Medical Device Sales Jump in Emerging Markets, Organizations Embrace Outsourcing Clinical Activities
9. Agricultural Biotechnology: Emerging Technologies and Global Markets
10. Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets
11. Wound Care Management Market to 2018 - Advanced Wound Care Modalities and an Expanding Patient Base Create Significant Growth Opportunities in Emerging Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):